Novo Nordisk A/S (NOVO-B.CO)

Copenhagen - Copenhagen Delayed Price. Currency in DKK
276.90-5.20 (-1.84%)
At close: 10:59 AM EDT
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close282.10
Bid277.40 x
Ask277.50 x
Day's Range276.70 - 288.90
52wk Range263.10 - 406.70
1y Target EstN/A
Market Cap697.64B
P/E Ratio (ttm)19.61
Avg Vol (3m)3,750,616
Dividend & YieldN/A (N/A)
Earnings DateN/A
  • Reuters2 hours ago

    Lilly results hurt by disappointing Humalog, animal health sales

    Eli Lilly and Co's quarterly results were badly hurt by disappointing sales of its Humalog insulin and animal health products, but the company on Tuesday reaffirmed its full-year earnings forecast. Global sales of Humalog fell 9 percent to $641 million in the third quarter ended Sept. 30, well below Wall Street forecasts of $732 million, as Lilly cut the drug's U.S. price to better compete with other mealtime insulins, including Novo Nordisk's widely-used NovoLog. Sales of Lilly's animal health products fell 9 percent to $706 million, about $97 million shy of Wall Street forecasts, in large part because wholesalers had already built up inventories of the products in the prior quarter, the company said.

  • Market Realist2 hours ago

    How Much Is the Return Opportunity for Novo Nordisk in 3Q16?

    A Bloomberg survey of two brokerage houses on October 24, 2016, reflected a 50% “buy” rating and a 50% “hold” rating for the stock.

  • Get Paid While You Wait: 3 Top Dividend Stocks in Big Pharma
    Motley Fool8 days ago

    Get Paid While You Wait: 3 Top Dividend Stocks in Big Pharma

    Looking for above-average dividend stocks? These big pharma companies offer yields above 3%, and they could climb much higher.